Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Not Recruiting

Trial ID: NCT02348216


This study will be separated into 3 distinct phases designated as the Phase 1 study, Phase 2 pivotal study (Cohort 1 and Cohort 2), and Phase 2 safety management study (Cohort 3 and Cohort 4, Cohort 5 and Cohort 6). The primary objectives of this study are: - Phase 1 Study: Evaluate the safety of axicabtagene ciloleucel regimens - Phase 2 Pivotal Study; Evaluate the efficacy of axicabtagene ciloleucel - Phase 2 Safety Management Study: Assess the impact of prophylactic regimens or earlier interventions on the rate and severity of cytokine release syndrome (CRS) and neurologic toxicities Subjects who received an infusion of KTE-C19 will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968.

Official Title

A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma

Stanford Investigator(s)

Michael Khodadoust
Michael Khodadoust

Assistant Professor of Medicine (Oncology) and of Dermatology

Hans-Christoph Becker, MD, FSABI, FSCCT

Clinical Professor, Radiology


Key Inclusion Criteria

   1. Histologically confirmed:

      - Diffuse Large B Cell Lymphoma (DLBCL)

      - Primary Mediastinal Large B Cell Lymphoma (PMBCL)

      - Transformation Follicular Lymphoma (TFL)

      - High grade B-cell lymphoma (HGBCL)

   2. Chemotherapy-refractory disease, defined as one of more of the following:

      - No response to last line of therapy i. Progressive disease (PD) as best response
      to most recent therapy regimen ii. Stable disease (SD) as best response to most
      recent therapy with duration no longer than 6 month from last dose of therapy OR

      - Refractory post-autologous stem cell transplant (ASCT) i. Disease progression or
      relapsed less than or equal to 12 months of ASCT (must have biopsy proven
      recurrence in relapsed individuals) ii. If salvage therapy is given post-ASCT,
      the individual must have had no response to or relapsed after the last line of

   3. Individuals must have received adequate prior therapy including at a minimum:

      - anti-CD20 monoclonal antibody unless investigator determines that tumor is
      CD20-negative and

      - an anthracycline containing chemotherapy regimen

      - for individual with transformed FL must have chemorefractory disease after
      transformation to DLBCL.

   4. At least one measurable lesion per revised IWG Response Criteria

   5. Eastern cooperative oncology group (ECOG) performance status of 0 or 1

   6. Absolute neutrophil count (ANC) ≥ 1000/uL

   7. Absolute lymphocyte count ≥ 100/uL

   8. Platelet count ≥ 75,000/uL

   9. Adequate renal, hepatic, pulmonary and cardiac function defined as:

      - Creatinine clearance (as estimated by Cockcroft Gault) > 60 mL/min

      - Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5 upper
      limit of normal (ULN)

      - Total bilirubin < 1.5 mg/dL, except in individuals with Gilbert's syndrome

      - Cardiac ejection fraction >50%, no evidence of pericardial effusion as determined
      by an echocardiogram (ECHO), and no clinically significant pleural effusion

      - Baseline oxygen saturation >92% on room air

10. All individuals or legally appointed representatives/caregivers, must personally sign
   and date the Institutional Review Board (IRB)/Independent Ethics Committee (IEC)
   approved consent form before initiating any study specific procedures or activities.

11. Relapsed or refractory large B-cell lymphoma including DLBCL, PMBCL, TFL, and HGBCL
   after two systemic lines of therapy

Key Exclusion Criteria

   1. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g.
   cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3

   2. History of allogeneic stem cell transplantation

   3. Prior CAR therapy or other genetically modified T cell therapy

   4. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or
   requiring IV antimicrobials for management. Simple urinary tract infection (UTI) and
   uncomplicated bacterial pharyngitis are permitted if responding to active treatment

   5. History of human immunodeficiency virus (HIV) infection or acute or chronic active
   hepatitis B or C infection. Individuals with history of hepatitis infection must have
   cleared their infection as determined by standard serological and genetic testing per
   current Infectious Diseases Society of America (IDSA) guidelines

   6. Individuals with detectable cerebrospinal fluid malignant cells, or brain metastases,
   or with a history of central nervous system (CNS) lymphoma or primary CNS lymphoma,
   cerebrospinal fluid malignant cells or brain metastases

   7. History or presence of CNS disorder such as seizure disorder, cerebrovascular
   ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS

Note: Other protocol defined Inclusion/Exclusion criteria may apply.


biological: axicabtagene ciloleucel

drug: Fludarabine

drug: Cyclophosphamide

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Physician Referrals

New Trial Alerts

Receive email alerts when trials open to patients.